Zevra Therapeutics Inc at Cantor Fitzgerald Global Healthcare Conference Transcript
Good afternoon, everyone. My name is Carvey, a research associate here at Cantor. Thank you for coming. With Cliff and Josh. Well, before beginning, can we talk a little bit about the company from a higher-level perspective, what's your strategic vision, and maybe some of the major catalysts in coming years?
Yeah. Thank you, and thank you for having us, Carvey. We appreciate the opportunity. Zevra Therapeutics has gone through quite a transformation over the last few years, very much focused on rare disease. And part of that vision is continuing to build our pipeline around ultra rare products that we can commercialize ourselves. In addition to that, from our legacy of product development, we also have internally source candidates in that pipeline as well. And over the six to nine months, I'd just say there's a lot of great catalysts coming up that we think will be a lot of interest to investors.
Our lead product in development right
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
